Part II: Treatment of primary malignant non-Wilms' renal tumours in children

Lancet Oncology

Volumn 8, Issue 9, 2007, Pages 842-848

  Ahmed, Hashim Uddin ^b   Arya, Manit ^a,b   Levitt, Gill ^a   Duffy, Patrick G ^a   Sebire, Neil J ^a   Mushtaq, Imran ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CLEAR CELL SARCOMA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ECHOGRAPHY; HEMATOLOGIC DISEASE; HUMAN; INTERHOSPITAL COOPERATION; INTERNATIONAL COOPERATION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MEDICAL SPECIALIST; MEDULLARY CARCINOMA; MESOBLASTIC NEPHROMA; MOLECULAR BIOLOGY; MORBIDITY; NEPHRECTOMY; NEPHROBLASTOMA; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOID TUMOR; TREATMENT DURATION;

CARCINOMA, MEDULLARY; CARCINOMA, RENAL CELL; CHILD; HUMANS; KIDNEY NEOPLASMS; LYMPH NODE EXCISION; NEPHRECTOMY; NEPHROMA, MESOBLASTIC; RHABDOID TUMOR; SARCOMA, CLEAR CELL; SURVIVAL RATE; WILMS TUMOR;

EID: 34548256736     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70276-0     Document Type: Review

References (73)

1. Parkin D., Kramarova E., Draper G., et al. International incidence of childhood cancer, volume II. IARC Scientific Publications No.144 (1998), International Agency for Research on Cancer, Lyon
2. Broecker B. Non-Wilms renal tumors in children. Urol Clin North Am 27 (2000) 463-469
3. Lowe L., Isuani B., Heller R., et al. Pediatric renal masses: Wilms tumor and beyond. Radiographics 20 (2000) 1585-1603
4. Perlman E. Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol 8 (2005) 320-338
5. Raney R., Palmer N., Sutow W., et al. Renal cell carcinoma in children. Med Pediatr Oncol 11 (1983) 91-98
6. Aronson D., Medary I., Finlay J., et al. Renal cell carcinoma in childhood and adolescence: a retrospective survey for prognostic factors in 22 cases. J Pediatr Surg 31 (1996) 183-186
7. Pastore G., Znaor A., Spreafico F., Graf N., Pritchard-Jones K., and Steliarova-Foucher E. Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 42 (2006) 2103-2114
8. Chan H., Daneman A., Gribbin M., and Martin D. Renal cell carcinoma in the first two decades of life. Pediatr Radiol 13 (1983) 324-328
9. Aronson D., Medary I., Finlay J., Herr H., Exelby P., and La Quaglia M. Renal cell carcinoma in childhood and adolescence: a retrospective survey for prognostic factors in 22 cases. J Pediatr Surg 31 (1996) 183-186
10. Estrada C., Suthar A., Eaton S., and Cilento Jr. B. Renal cell carcinoma: Children's Hospital Boston experience. Urology 66 (2005) 1296-1300
11. Indolfi P., Terenziani M., Casale F., et al. Renal cell carcinoma in children: a clinicopathologic study. J Clin Oncol 21 (2003) 530-535
12. Androulakakis P., Polychronopoulou-Androulakaki S., Michael V., Stephanidis A., and Yannakis C. Renal cell carcinoma in children under 14 years old: long-term survival. BJU Int 83 (1999) 654-657
13. Raney Jr. R., Palmer N., Sutow W., Baum E., and Ayala A. Renal cell carcinoma in children. Med Pediatr Oncol 11 (1983) 91-98
14. Bruce J., and Gough D. Longterm follow-up of children with renal carcinoma. Br J Urol 65 (1990) 446-448
15. Freedman A., Vates T., Stewart T., Padiyar N., Perlmutter A., and Smith C. Renal cell carcinoma in children: the Detroit experience. J Urol 155 (1996) 1708-1710
16. Asanuma H., Nakai H., Takeda M., et al. Renal cell carcinoma in children: experience at a single institution in Japan. J Urol 162 (1999) 1402-1405
17. Ramphal R., Pappo A., Zielenska M., et al. Paediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the MiT transcription factor family. Am J Clin Pathol 126 (2006) 349-364
18. Cook A., Lorenzo A., Salle J., et al. Pediatric renal cell carcinoma: single institution 25-year case series and initial experience with partial nephrectomy. J Urol 175 (2006) 1456-1460
19. Argani P., and Ladanyi M. The evolving story of renal translocation carcinoma. Am J Clin Pathol 126 (2006) 332-334
20. Meloni A., Dobbs R., Pontes J., et al. Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet 65 (1993) 1-6
21. Argani P., Antonescu C., Couturier J., et al. PRCC-TFE3 renal carcinomas. Morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Path 26 (2002) 1553-1566
22. Argani P., and Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 25 (2005) 363-378
23. Argani P., and Ladanyi M. Recent advances in paediatric renal neoplasia. Adv Anat Path 10 (2003) 243-260
24. Ficarra V., Righetti R., Pilloni S., et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 41 (2002) 190-198
25. Geller J., and Dome J. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer 101 (2004) 1575-1583
26. Atzpodien J., Schmitt E., Gertenback U., et al. Adjuvant treatment with interleukin-2 and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92 (2005) 843-846
27. MacArthur C., Issacs H., Miller J., et al. Pediatric renal cell carcinoma: a complete response to recombinant interleukin-2 in a child with metastatic disease at diagnosis. Med Pediatr Oncol 23 (1994) 365-371
28. Bauer M., Reaman G., Hank J., et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 75 (1995) 2959-2965
29. Ladanyi M., Lui M., Antonescu C., et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20 (2001) 48-57
30. Bukowski R. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 27 (2000) 204-212
31. Nanus D., Garino A., Milowsky M., et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101 (2004) 1545-1551
32. Tsuda M., Davis I., Argani P., et al. TFE3 fusions activate MET signaling by transcriptional u-pregulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 67 (2007) 919-929
33. Ismail-zade R., Zhavrid E., and Potapnev M. Whole body hyperthermia in adjuvant therapy of children with renal cell carcinoma. Pediatr Blood Cancer 44 (2005) 679-681
34. Uchiyama M., Iwafuchi M., Yagi M., et al. Treatment of childhood renal cell carcinoma with lymph node metastasis: two cases and a review of literature. J Surg Oncol 75 (2000) 266-269
35. Green D., Breslaw N., Beckwith J., et al. Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. J Clin Oncol 12 (1994) 2132-2137
36. D'Angio G., Breslow W., Beckwith J., et al. The treatment of Wilms' tumor: results of the third National Wilms' Tumor Study. Cancer 64 (1989) 349-360
37. Argani P., Perlman E., Breslow N., et al. Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumour Study Pathology Center. Am J Surg Path 24 (2000) 4-18
38. Mitchell C., Jones P., Kelsy A., et al. The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study. Br J Cancer 83 (2000) 602-608
39. Tournade M., Com-Nougué C., de Kraker J., et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 19 (2001) 488-500
40. Seibel N., Li S., Breslow N., et al. Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. J Clin Oncol 22 (2004) 468-473
41. Green D., Breslow N., Beckwith J., et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 16 (1998) 237-245
42. Green D., Breslow N., Evans I., et al. The effect of chemotherapy dose-intensity on the hematological toxicity of the treatment for Wilms' tumor: a report from the National Wilms' Tumor Study. Am J Pediatr Hematol Oncol 16 (1994) 207-212
43. Green D., Grigorien Y., Nan B., et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 19 (2001) 1926-1934
44. Bolande R. Congenital mesoblastic nephroma of infancy. Perspect Pediatr Pathol 1 (1973) 227-250
45. Howell C., Othersen H., Kiviat N., Norkool P., Beckwith J., and D'Angio G. Therapy and outcome in 51 children with mesoblastic nephroma: a report of the National Wilms' Tumor Study. J Pediatr Surg 17 (1982) 826-831
46. Fu Y., and Kay S. Congenital mesoblastic nephroma and its recurrence. Arch Pathol 96 (1973) 66-70
47. Gonzalez-Crussi F., Sotelo-Avila C., and Kidd J. Malignant mesenchymal nephroma of infancy: report of a case with pulmonary metastases. Am J Surg Pathol 4 (1980) 185-190
48. Patel Y., Mitchell C., and Hitchcock R. Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. Urology 61 (2003) 1260
49. Vujanic G., Delemarre J., Moeslichan S., et al. Mesoblastic nephroma metastatic to the lungs and heart-another face of this peculiar lesion: case report and review of the literature. Pediatr Pathol 13 (1993) 143-153
50. Heidelberger K., Ritchey M., Dauser R., McKeever P., and Beckwith J. Congenital mesoblastic nephroma metastatic to the brain. Cancer 72 (1993) 2499-2502
51. Joshi V., Kasznica J., and Walters T. Atypical mesoblastic nephroma. Pathologic characterization of a potentially aggressive variant of conventional congenital mesoblastic nephroma. Arch Pathol Lab Med 110 (1986) 100-106
52. Gormley T., Skoog S., Jones R., and Maybee D. Cellular congenital mesoblastic nephroma: what are the options. J Urol 142 (1989) 479-483
53. Beckwith J., and Weeks D. Congenital mesoblastic nephroma. When should we worry?. Arch Pathol Lab Med 110 (1986) 98-99
54. Furtwaengler R., Reinhard H., Leuschner I., et al. Mesoblastic nephroma-a report from the Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Cancer 106 (2006) 2275-2283
55. Steinfeld A., Crowley C., O'Shea P., and Tefft M. Recurrent and metastatic mesoblastic nephroma in infancy. J Clin Oncol 2 (1984) 956-960
56. Loeb D., Hill D., and Dome J. Complete response of recurrent cellular congenital mesoblastic nephroma to chemotherapy. J Pediatr Hematol Oncol 24 (2002) 478-481
57. McCahon E., Sorensen P., Davis J., Rogers P., and Schultz K. Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol 40 (2003) 288-292
58. Kurkchubasche A., Halvorson E., Forman E., et al. The role of preoperative chemotherapy in the treatment of infantile fibrosarcoma. J Pediatr Surg 35 (2000) 880-883
59. Palmer N., and Sutow W. Clinical aspects of the rhabdoid tumour of the kidney: a report of the National Wilms' Tumour Study Group. Med Pediatr Oncol 11 (1983) 242-245
60. Weeks D., Beckwith J., Mierau G., et al. Rhabdoid tumour of kidney: a report of 111 cases from the NWTS pathology center. Am J Surg Pathol 13 (1989) 439-458
61. Mitchell C., Jones P., Kelsey A., et al. The treatment of Wilms' tumour: results of the UK Children's Cancer Study Group (UKCCSG) second Wilms' tumour study. Br J Cancer 83 (2000) 605-608
62. Tomlinson G., Breslow N., Dome J., et al. Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 23 (2005) 7642-7645
63. Kodet R., Newton W., Sachs N., et al. Rhabdoid tumors of soft tissues: a clinicopathologic study of 26 cases enrolled on the Intergroup Rhabdomyosarcoma Study. Hum Pathol 22 (1991) 674-684
64. Hilden J., Watterson J., Longee D., et al. Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. J Neurooncol 40 (1998) 265-275
65. Waldron P., Rodgers B., Kelly M., and Womer R. Successful treatment of a patient with stage IV rhabdoid tumor of the kidney: case report and review. J Pediatr Hematol Oncol 21 (1999) 53-57
66. Wagner L., Hill D., Fuller C., et al. Treatment of metastatic rhabdoid tumor of the kidney. J Pediatr Hematol Oncol 24 (2002) 385-388
67. Strouse J., Spevak M., Mack A., Arceci R., Small D., and Loeb D. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 44 (2005) 407-411
68. Guinan P., Sobin L., Algaba F., et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 992-993
69. Pirich L., Chou P., and Walterhouse D. Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma. J Pediatr Hematol Oncol 21 (1999) 67-69
70. Selby D., Simon C., Foley J., Thompson I., and Baddour R. Renal medullary carcinoma: can early diagnosis lead to long-term survival?. J Urol 163 (2000) 1238
71. Strouse J., Spevak M., Mack A., Arceci R., Small D., and Loeb D. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 44 (2005) 407-411
72. Bell M. Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma. Pediatr Blood Cancer 47 (2006) 228
73. Huang C., Cutcliffe C., Coffin C., et al. Classification of malignant pediatric renal tumors by gene expression. Pediatr Blood Cancer 46 (2006) 728-738